|
||||||||||||||||||
Gauging a company’s exposure to lingering Covid impacts – and lasting Covid changes – will be an important component of research in 2022. Another important Covid carry-over is that we expect cyclicals to outperform in the first half of the year, especially given expected ongoing economic reopening and above-average GDP growth.
|
||||||||||||||||||
|
||||||||||||||||||
|